Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Ex-Beckman Coulter CEO joins Hologic's board

This article was originally published in Clinica

  • News

Executive Summary

Women’s health firm Hologic has appointed Scott Garrett, previously chairman, CEO and president of diagnostic company Beckman Coulter, to its newly-expanded board. He will serve on the company’s corporate development committee. Hologic’s board now comprises 10 directors, eight of whom are independent. Mr Garrett was at Beckman Coulter for almost 10 years, but quit his roles abruptly in 2010 (www.clinica.co.uk, 9 September 2010). The company was acquired by Danaher in 2011 (www.clinica.co.uk, 7 February 2011). Before joining Beckman, he was vice-chairman and interim CEO of Kendro Laboratory Products; and previously, chairman, president and CEO of Dade Behring. Mr Garrett is currently an operating partner with healthcare-focused private equity firm Water Street Healthcare Partners.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

See All
UsernamePublicRestriction

Register

MT100365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By